We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+18.76%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
+$221M
(+23%)
Cap. Flow
+$85.7M
Cap. Flow
% of AUM
7.26%
Top 10 Holdings %
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2
Avg Time Held
1
year
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xencor
XNCR
|
+$45.6M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$38.9M |
| 3 |
Third Harmonic Bio
THRD
|
+$29.9M |
| 4 |
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Structure Therapeutics
GPCR
|
+$14.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$41.8M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$9.12M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$8.65M |
| 4 |
C4 Therapeutics
CCCC
|
+$5.9M |
| 5 |
Silence Therapeutics
SLN
|
+$4.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$5.48B
| $138M | 11.73% |
3,670,206
| – | – |
2024 Q1
2 quarters
|
|
2
Dyne Therapeutics
DYN
$2.81B
| $95.2M | 8.07% |
2,650,150
| – | – |
2023 Q1
6 quarters
|
|
3
Cogent Biosciences
COGT
$4.88B
| $75.2M | 6.37% |
6,964,375
| – | – |
2021 Q4
11 quarters
|
|
4
Abivax
ABVX
$7.68B
| $69.8M | 5.91% |
6,056,596
| – | – |
2023 Q4
3 quarters
|
|
5
Edgewise Therapeutics
EWTX
$4.02B
| $56.4M | 4.78% |
2,112,984
-159,744
| -7% | -$3.18M |
2024 Q1
2 quarters
|
|
|
6
Silence Therapeutics
SLN
$558M
| $55.2M | 4.67% |
3,033,560
-261,790
| -8% | -$4.87M |
2022 Q3
8 quarters
|
|
7
Savara
SVRA
$978M
| $52.4M | 4.44% |
12,362,205
| – | – |
2023 Q3
4 quarters
|
|
8
Keros Therapeutics
KROS
$219M
| $51.1M | 4.33% |
879,344
| – | – |
2024 Q1
2 quarters
|
|
|
9
Xencor
XNCR
$1.74B
| $48.8M | 4.14% |
+2,427,138
| New | +$45.6M |
2024 Q3
0 quarters
|
|
10
Tyra Biosciences
TYRA
$1.29B
| $46.8M | 3.96% |
1,989,103
| – | – |
2021 Q4
11 quarters
|
|
|
11
Structure Therapeutics
GPCR
$1.56B
| $46.7M | 3.95% |
1,063,000
+368,453
| +53% | +$14.2M |
2023 Q1
6 quarters
|
|
12
Ocular Therapeutix
OCUL
$1.58B
| $46.3M | 3.92% |
5,319,148
| – | – |
2024 Q1
2 quarters
|
|
|
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
| $46.2M | 3.92% |
2,890,816
| – | – |
2023 Q3
4 quarters
|
|
14
DELISTED
Tourmaline Bio
TRML
| $38M | 3.22% |
1,477,593
| – | – |
2023 Q4
3 quarters
|
|
|
15
DELISTED
Third Harmonic Bio
THRD
| $32.7M | 2.77% |
+2,415,000
| New | +$29.9M |
2024 Q3
0 quarters
|
|
16
DELISTED
Astria Therapeutics
ATXS
| $30.4M | 2.58% |
2,761,861
| – | – |
2024 Q1
2 quarters
|
|
|
17
Mineralys Therapeutics
MLYS
$1.84B
| $29.9M | 2.53% |
2,470,265
-714,920
| -22% | -$8.65M |
2024 Q1
2 quarters
|
|
18
Kura Oncology
KURA
$855M
| $27.8M | 2.36% |
1,423,642
| – | – |
2022 Q1
10 quarters
|
|
19
DELISTED
Soleno Therapeutics
SLNO
| $27.8M | 2.35% |
550,000
| – | – |
2024 Q1
2 quarters
|
|
20
Compass Pathways
CMPS
$1.56B
| $24.3M | 2.06% |
3,858,000
| – | – |
2023 Q3
4 quarters
|
|
21
Disc Medicine
IRON
$2.14B
| $23.9M | 2.03% |
486,957
| – | – |
2024 Q2
1 quarter
|
|
|
22
Fulcrum Therapeutics
FULC
$280M
| $18.7M | 1.59% |
+5,250,000
| New | +$38.9M |
2024 Q3
0 quarters
|
|
|
23
MBX Biosciences
MBX
$2.35B
| $16.9M | 1.43% |
+650,000
| New | +$14.9M |
2024 Q3
0 quarters
|
|
24
Amylyx Pharmaceuticals
AMLX
$3.39B
| $15M | 1.27% |
+4,643,812
| New | +$10.4M |
2024 Q3
0 quarters
|
|
25
DELISTED
Adverum Biotechnologies
ADVM
| $14.1M | 1.19% |
2,008,339
-1
| -0% | -$7 |
2024 Q1
2 quarters
|
|
Similar funds
CCMIC
TCG Crossover Management's Q3 2024 Portfolio in Review
As of Q3 2024, TCG Crossover Management held 38 positions worth $1.18B, up 23% from $960M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
TCG Crossover Management deployed $85.7M of net new capital in Q3 2024, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Xencor: 2,427,138 shares worth $48.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $9.12M trimmed.
- TCG Crossover Management's largest Q3 2024 buy was Xencor: 2,427,138 shares worth $48.8M.
- TCG Crossover Management added most to Structure Therapeutics in Q3 2024, an estimated $14.2M increase.
- TCG Crossover Management's biggest Q3 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $9.12M.
- TCG Crossover Management fully exited Madrigal Pharmaceuticals in Q3 2024, selling an estimated $41.8M.
- TCG Crossover Management's ten largest holdings make up 58% of its $1.18B portfolio in Q3 2024.
- TCG Crossover Management opened 6 new positions and closed 2 in Q3 2024.
- TCG Crossover Management's portfolio value rose 23% quarter-over-quarter to $1.18B.
Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.